Home LiteratureArticle Details
PMID: 17551814 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

The Warburg effect and its cancer therapeutic implications.

Journal of bioenergetics and biomembranes ·Vol. 39 ·No. 3 ·2007-06-00 ·Pages 267-74

Chen Z, Lu W, Garcia-Prieto C, Huang P

Abstract

Increased aerobic glycolysis in cancer, a phenomenon known as the Warburg effect, has been observed in various tumor cells and represents a major biochemical alteration associated with malignant transformation. Although the exact molecular mechanisms underlying this metabolic change remain to be elucidated, the profound biochemical alteration in cancer cell energy metabolism provides exciting opportunities for the development of therapeutic strategies to preferentially kill cancer cells by targeting the glycolytic pathway. Several small molecules capable of inhibiting glycolysis in experimental systems have been shown to have promising anticancer activity in vitro and in vivo. This review article provides a brief summary of our current understanding of the Warburg effect, the underlying mechanisms, and its influence on the development of therapeutic strategies for cancer treatment.

MeSH Terms
Animals Antineoplastic Agents/therapeutic use Cell Transformation, Neoplastic DNA, Mitochondrial/metabolism Energy Metabolism/drug effects,physiology Glycolysis Humans Mitochondria/physiology Neoplasms/drug therapy,metabolism Oncogenes/physiology Signal Transduction
Chemicals
Antineoplastic Agents DNA, Mitochondrial
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Chen Zhao
Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77030, USA.
Lu Weiqin
Garcia-Prieto Celia
Huang Peng
References (63)
63 references, click to expand
  1. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.
    Nature. 1995 Aug 17;376(6541):599-602 PMID: 7637810
  2. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.
    Genes Dev. 2001 Sep 1;15(17):2203-8 PMID: 11544177
  3. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
    Leukemia. 2004 Dec;18(12):1934-40 PMID: 15483672
  4. On the origin of cancer cells.
    Science. 1956 Feb 24;123(3191):309-14 PMID: 13298683
  5. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements.
    Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5992-7 PMID: 15840712
  6. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention.
    Biochim Biophys Acta. 2002 Sep 10;1555(1-3):14-20 PMID: 12206885
  7. Contributions of glycolysis and oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D hepatoma cells.
    Cancer Res. 1984 Dec;44(12 Pt 1):5702-6 PMID: 6498833
  8. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species.
    FASEB J. 1997 Apr;11(5):388-95 PMID: 9141507
  9. Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
    Am J Pharmacogenomics. 2005;5(5):293-302 PMID: 16196499
  10. Mitochondrial dysfunction is a common phenotype in aging and cancer.
    Ann N Y Acad Sci. 2004 Jun;1019:260-4 PMID: 15247025
  11. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted.
    Br J Cancer. 2006 Feb 27;94(4):578-85 PMID: 16465194
  12. Why do cancers have high aerobic glycolysis?
    Nat Rev Cancer. 2004 Nov;4(11):891-9 PMID: 15516961
  13. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism.
    Biochem Pharmacol. 1998 Oct 1;56(7):841-9 PMID: 9774146
  14. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.
    Genomics. 2004 Dec;84(6):1014-20 PMID: 15533718
  15. Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis.
    Biochem Biophys Res Commun. 1997 Jun 27;235(3):739-42 PMID: 9207231
  16. Characterization of the rat type III hexokinase gene promoter. A functional octamer 1 motif is critical for basal promoter activity.
    J Biol Chem. 1999 Oct 29;274(44):31700-6 PMID: 10531380
  17. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase.
    J Biol Chem. 1995 Jul 14;270(28):16918-25 PMID: 7622509
  18. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.
    Cell Metab. 2006 Mar;3(3):177-85 PMID: 16517405
  19. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells.
    J Cell Biochem. 2005 May 1;95(1):45-52 PMID: 15770658
  20. Substrate oxidation and ATP supply in AS-30D hepatoma cells.
    Arch Biochem Biophys. 2000 Mar 1;375(1):21-30 PMID: 10683245
  21. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions.
    Cancer Chemother Pharmacol. 2004 Feb;53(2):116-22 PMID: 14605866
  22. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function.
    J Exp Biol. 2003 Jun;206(Pt 12):2049-57 PMID: 12756287
  23. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130.
    FEBS Lett. 1991 Oct 7;291(1):55-7 PMID: 1936251
  24. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.
    Biochem Biophys Res Commun. 2004 Nov 5;324(1):269-75 PMID: 15465013
  25. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt.
    Oncogene. 2006 Aug 7;25(34):4683-96 PMID: 16892082
  26. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival.
    Mol Cell Biol. 2003 Oct;23(20):7315-28 PMID: 14517300
  27. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.
    Cancer Lett. 2001 Nov 8;173(1):83-91 PMID: 11578813
  28. Mitochondrial mutations in cancer.
    Oncogene. 2006 Aug 7;25(34):4647-62 PMID: 16892079
  29. TIGAR, a p53-inducible regulator of glycolysis and apoptosis.
    Cell. 2006 Jul 14;126(1):107-20 PMID: 16839880
  30. Glucose catabolism in African trypanosomes. Evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs.
    J Biol Chem. 1993 Feb 15;268(5):3654-61 PMID: 8429041
  31. Hypoxia--a key regulatory factor in tumour growth.
    Nat Rev Cancer. 2002 Jan;2(1):38-47 PMID: 11902584
  32. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
    Leukemia. 2005 Dec;19(12):2153-8 PMID: 16193082
  33. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.
    Cancer Cell. 2006 Jun;9(6):425-34 PMID: 16766262
  34. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.
    Cancer Cell. 2005 Jan;7(1):77-85 PMID: 15652751
  35. Hexokinase-II expression in untreated oral squamous cell carcinoma: comparison with FDG PET imaging.
    Ann Nucl Med. 2005 Jun;19(4):335-8 PMID: 16097646
  36. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.
    Cancer Res. 2002 Jul 15;62(14):3909-13 PMID: 12124317
  37. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
    J Clin Oncol. 2002 Oct 15;20(20):4150-9 PMID: 12377958
  38. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
    Strahlenther Onkol. 2005 Aug;181(8):507-14 PMID: 16044218
  39. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Clin Cancer Res. 2004 Oct 1;10(19):6661-8 PMID: 15475456
  40. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications.
    Leukemia. 2003 Aug;17(8):1437-47 PMID: 12886229
  41. Hypersensitization of tumor cells to glycolytic inhibitors.
    Biochemistry. 2001 May 8;40(18):5542-7 PMID: 11331019
  42. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.
    Cancer Res. 2005 Jan 15;65(2):613-21 PMID: 15695406
  43. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes.
    Science. 1987 Mar 20;235(4795):1492-5 PMID: 3103217
  44. Glycolysis inhibition for anticancer treatment.
    Oncogene. 2006 Aug 7;25(34):4633-46 PMID: 16892078
  45. Mitochondrial tumour suppressors: a genetic and biochemical update.
    Nat Rev Cancer. 2005 Nov;5(11):857-66 PMID: 16327764
  46. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.
    Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):535-9 PMID: 16912547
  47. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo.
    Cancer Res. 2004 Jan 1;64(1):31-4 PMID: 14729604
  48. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".
    Cancer Chemother Pharmacol. 2006 Dec;58(6):725-34 PMID: 16555088
  49. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
    Drugs Today (Barc). 2003 Mar;39(3):157-74 PMID: 12730701
  50. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle.
    FEBS Lett. 1999 Jul 30;456(1):113-8 PMID: 10452541
  51. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Cancer Chemother Pharmacol. 1989;25(1):32-6 PMID: 2590999
  52. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C).
    Biochem Pharmacol. 2002 Dec 15;64(12):1745-51 PMID: 12445863
  53. p53 regulates mitochondrial respiration.
    Science. 2006 Jun 16;312(5780):1650-3 PMID: 16728594
  54. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
    Eur J Cancer. 2003 Nov;39(16):2334-40 PMID: 14556925
  55. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase.
    FEBS J. 2006 May;273(9):1975-88 PMID: 16640561
  56. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.
    Oncogene. 2006 Aug 7;25(34):4777-86 PMID: 16892090
  57. The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction.
    Mol Biol Cell. 2003 Aug;14(8):3082-96 PMID: 12925748
  58. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.
    J Natl Cancer Inst. 1981 Mar;66(3):497-9 PMID: 6937706
  59. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer.
    Clin Lab. 2005;51(5-6):257-73 PMID: 15991799
  60. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis.
    Cancer Res. 2005 Jan 1;65(1):203-9 PMID: 15665296
  61. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP.
    J Biol Chem. 1988 Nov 25;263(33):17422-8 PMID: 3182854
  62. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
    Eur J Cancer. 2004 Mar;40(5):667-72 PMID: 15010066
  63. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.
    J Cell Biol. 2006 Dec 18;175(6):913-23 PMID: 17158952
Article Info
Journal
Journal of bioenergetics and biomembranes
Abbr.
J Bioenerg Biomembr
ISSN
0145-479X
DOI
10.1007/s10863-007-9086-x
Published
2007-06-00
Pages
267-74
Language
English
Region
United States
NLM ID
7701859
Subset
IM
Grants
NCI NIH HHS · CA085563 · United States
NCI NIH HHS · CA100428 · United States
NCI NIH HHS · CA109041 · United States
External Links
PubMed source DOI: 10.1007/s10863-007-9086-x View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2